Jaewon Hyung

494 total citations
32 papers, 272 citations indexed

About

Jaewon Hyung is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Jaewon Hyung has authored 32 papers receiving a total of 272 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 15 papers in Surgery. Recurrent topics in Jaewon Hyung's work include Cholangiocarcinoma and Gallbladder Cancer Studies (10 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Gallbladder and Bile Duct Disorders (7 papers). Jaewon Hyung is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (10 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Gallbladder and Bile Duct Disorders (7 papers). Jaewon Hyung collaborates with scholars based in South Korea, United States and Germany. Jaewon Hyung's co-authors include Changhoon Yoo, Baek‐Yeol Ryoo, Kyu‐pyo Kim, Heung-Moon Chang, Bum Jun Kim, Seongjoon Park, Jae Ho Jeong, Tae Jun Song, Hyungwoo Cho and Do Hyun Park and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Hepatology.

In The Last Decade

Jaewon Hyung

26 papers receiving 266 citations

Peers

Countries citing papers authored by Jaewon Hyung

Since Specialization

Citations

This map shows the geographic impact of Jaewon Hyung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaewon Hyung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaewon Hyung more than expected).

Fields of papers citing papers by Jaewon Hyung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaewon Hyung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaewon Hyung. The network helps show where Jaewon Hyung may publish in the future.

Co-authorship network of co-authors of Jaewon Hyung

This figure shows the co-authorship network connecting the top 25 collaborators of Jaewon Hyung. A scholar is included among the top collaborators of Jaewon Hyung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaewon Hyung. Jaewon Hyung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Predictive value of EBV-positivity in patients with gastric cancer treated with first-line nivolumab plus chemotherapy 2025 ·Gastric Cancer ·Hyung‐Don Kim, Soyeon Kim, (unknown), Yuna Lee, Jaewon Hyung, (unknown), Jinho Shin, Young Soo Park, Min‐Hee Ryu	1
2	Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors 2025 ·European Journal of Nuclear Medicine and Molecular Imaging ·Hyehyun Jeong, (unknown), Jae Ho Jeong, Sangwon Han, Jaewon Hyung, Jin‐Hee Ahn, Kyung Hae Jung, (unknown), (unknown), Hee Jin Lee, (unknown), Dae Hyuk Moon	0
3	Predictive value of homologous recombination-related gene mutations in survival outcomes of first-line nivolumab plus chemotherapy for gastric cancer 2025 ·Gastric Cancer ·Yuna Lee, Hyung‐Don Kim, Sun Young Lee, (unknown), Jaewon Hyung, (unknown), Jinho Shin, Young Soo Park, Tae Won Kim, Min‐Hee Ryu	0
4	Impact of¹⁸F-FES PET/CT on Clinical Decisions in the Management of Recurrent or Metastatic Breast Cancer 2024 ·Journal of Nuclear Medicine ·(unknown), Jaewon Hyung, Sangwon Han, Jae Ho Jeong, (unknown), Tae-Kyung Yoo, Jisun Kim, Hee Jeong Kim, Il Yong Chung, (unknown), (unknown), (unknown), Hyehyun Jeong, Jin‐Hee Ahn, Kyung Hae Jung, (unknown), Dae Hyuk Moon	2
5	Discordant PD-L1 results between 28–8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy 2024 ·Gastric Cancer ·Hyung‐Don Kim, Jinho Shin, In Hye Song, Jaewon Hyung, (unknown), Min‐Hee Ryu, Young Soo Park	7
6	58P Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-based therapy: A pooled analysis of the NIFTY and NALIRICC trials 2024 ·Annals of Oncology ·(unknown), Anna Saborowski, Jaewon Hyung, (unknown), Il Hwan Kim, Henning Wege, Kwang Pyo Kim, Gunnar Folprecht, B-Y. Ryoo, (unknown), Jun Cheon, Thorsten Oliver Goetze, Hyewon Ryu, (unknown), Arndt Vogel	0
7	Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair 2024 ·Gastric Cancer ·(unknown), Hyung‐Don Kim, Jaewon Hyung, Young Soo Park, Min‐Hee Ryu	4
8	Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysis 2023 ·ESMO Open ·Jaewon Hyung, (unknown), (unknown), Shinkyo Yoon, Changhoon Yoo, Yong Sang Hong, Jae Ho Jeong, Tae Won Kim, Seong Woo Jeon, (unknown), Chan Kwon Jung, (unknown), Ji Hoon Kim, Sail Chun, Jin‐Hee Ahn	2
9	Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer 2023 ·JAMA Oncology ·Jaewon Hyung, Il Hwan Kim, Kyu‐pyo Kim, Baek‐Yeol Ryoo, Jae Ho Jeong, Myoung Joo Kang, Jaekyung Cheon, Byung Woog Kang, Hyewon Ryu, Ji Sung Lee, Kyung Won Kim, Ghassan K. Abou‐Alfa, Changhoon Yoo	42
10	Analysis of plasma circulating tumor DNA in borderline resectable pancreatic ductal adenocarcinoma treated with neoadjuvant modified FOLFIRINOX: Clinical relevance of DNA damage repair gene alterations. 2023 ·Journal of Clinical Oncology ·(unknown), Jaewon Hyung, Sang Soo Lee, Jae Ho Jeong, Baek‐Yeol Ryoo, Kyu‐pyo Kim, Changhoon Yoo	1
11	DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plus postoperative S-1: a sub-analysis of the phase 3 PRODIGY trial 2023 ·Gastric Cancer ·Jaewon Hyung, Hyungwoo Cho, Hyung‐Don Kim, Young Soo Park, (unknown), Min‐Hee Ryu, Yoon‐Koo Kang	5
12	Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection 2023 ·Cancer Research and Treatment ·(unknown), (unknown), Kyu‐pyo Kim, Baek‐Yeol Ryoo, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dae Wook Hwang, Jae Hoon Lee, Ki Byung Song, Song Cheol Kim, Seung‐Mo Hong, Jaewon Hyung, Changhoon Yoo	7
13	Recent Advances in Systemic Therapy for Advanced Intrahepatic Cholangiocarcinoma 2023 ·Liver Cancer ·Changhoon Yoo, Jaewon Hyung, Stephen L. Chan	12
14	Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability‒High Colon Cancer 2022 ·Cancer Research and Treatment ·Jaewon Hyung, Eun Jeong Cho, Jihun Kim, Jwa Hoon Kim, Jeong Eun Kim, Yong Sang Hong, (unknown), Chang Ohk Sung, Sun Young Kim	13
15	Beta-2 microglobulin as a prognostic factor of primary central nervous system lymphoma 2019 ·Blood Research ·Jaewon Hyung, Jung Yong Hong, Shin Kim, Jin Sook Ryu, Jooryung Huh, Cheolwon Suh	4
16	Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma 2019 ·Annals of Hematology ·Jaewon Hyung, Jung Yong Hong, Dok Hyun Yoon, Shin Kim, Jung Sun Park, Chan-Sik Park, Sang-wook Lee, Jeong Hoon Kim, Jin Sook Ryu, Jooryung Huh, Cheolwon Suh	8
17	Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin 2018 ·Cancer Research and Treatment ·Jaewon Hyung, Bum Jun Kim, Changhoon Yoo, (unknown), Jae Ho Jeong, Heung-Moon Chang, Baek‐Yeol Ryoo	19
18	Thiotepa, Busulfan, and Cyclophosphamide and Busulfan, Cyclophosphamide, Etoposide As Autologous Stem Cell Transplantation Conditioning Regimen in Primary Central Nervous System Lymphoma 2017 ·Blood ·Jaewon Hyung, Jung Yong Hong, Dok Hyun Yoon, Kyoungmin Lee, Shin Kim, Chan-Sik Park, Jooryung Huh, Jin‐Sook Ryu, Cheolwon Suh	0
19	Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients 2017 ·British Journal of Cancer ·Bum Jun Kim, Changhoon Yoo, Kyu‐pyo Kim, Jaewon Hyung, Seongjoon Park, Baek‐Yeol Ryoo, Heung-Moon Chang	55
20	Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients 2017 ·Cancer Chemotherapy and Pharmacology ·Bum Jun Kim, Jaewon Hyung, Changhoon Yoo, Kyu‐pyo Kim, Seong‐Joon Park, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dong Wan Seo, Sung Koo Lee, Myung‐Hwan Kim, Jin‐hong Park, Hyungwoo Cho, Baek‐Yeol Ryoo, Heung-Moon Chang	59

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact